Baseline demographics
| LixiLan-O | LixiLan-L | |||||
| NA n=371 | RoW n=796 | P value | NA n=196 | RoW n=535 | P value | |
| Age, years | 57.9 (10.1) | 58.6 (8.9) | 0.246 | 59.9 (9.2) | 60.0 (9.0) | 0.932 |
| Women, % | 45.8 (49.9) | 51.0 (50.0) | 0.098 | 48.0 (50.1) | 55.5 (49.7) | 0.070 |
| BMI, kg/m2 | 31.6 (4.7) | 31.8 (4.3) | 0.402 | 30.9 (4.3) | 31.2 (4.1) | 0.264 |
| Race, % | ||||||
| White | 81.1 (39.2) | 94.2 (23.3) | <0.001 | 73.0 (44.5) | 98.5 (12.1) | <0.001 |
| Black | 13.5 (34.2) | 3.5 (18.4) | <0.001 | 18.9 (39.2) | 0.2 (4.3) | <0.001 |
| Asian | 4.3 (20.3) | 0.3 (5.0) | <0.001 | 8.2 (27.5) | 0.7 (8.6) | <0.001 |
| Other | 1.1 (10.3) | 2.0 (14.0) | 0.203 | 0.0 (0.0) | 0.6 (7.5) | 0.082 |
| T2D duration, years | 10.0 (6.3) | 8.2 (5.3) | <0.001 | 12.5 (7.0) | 11.9 (6.6) | 0.257 |
| OADs, n | 1.5 (0.5) | 1.6 (0.5) | <0.001 | 1.3 (0.6) | 1.4 (0.6) | 0.477 |
| Insulin dose, units | 36.9 (8.6) | 34.4 (8.9) | 0.001 | 45.5 (12.1) | 46.4 (12.9) | 0.410 |
Data are presented as the mean (SD) or as indicated.
BMI, body mass index; NA, North America; OADs, oral antidiabetic drugs; RoW, rest of the world; SD, standard deviation; T2D, type 2 diabetes.